In a groundbreaking move, Canada has officially approved the use of psychedelics such as psilocybin and MDMA in therapeutic settings for treating PTSD and severe depression. Health Canada granted licenses to select clinics after positive trial outcomes.
The decision has been hailed by mental health professionals who argue that traditional antidepressants fail for many patients. These therapies will only be administered under supervision and after all conventional treatments are tried.
Mental health experts in South Asia, including India and Nepal, are watching closely. Some psychiatric associations have urged governments to begin regulated trials for similar treatments, especially in cases of war trauma and chronic depression.